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The effect of long-acting oxytetracycline treatment in the development of sequestra in contagious 
bovine pleuropneumonia (CBPP)-infected animals was determined. Thirty five clinically healthy zebu 
cattle, negative for CBPP antibodies (as tested by a competitive ELISA), were infected with Mycoplasma 
mycoides subsp. mycoides small colony variant - field isolate. All the animals were monitored for 
clinical signs of illness and regularly sampled for serological and bacteriological analysis. Nine animals 
were treated with long-acting tetracycline upon the first evidence of clinical signs of illness. The 26 
remaining animals were left untreated and served as control animals. Post-mortem examinations were 
performed to assess the presence or absence of CBPP gross lesions. The experimentation lasted for 10 
months during which, 13 animals (all untreated) died with acute lung lesions. When the 22 surviving 
animals (13 untreated and 9 treated) were slaughtered at the end of experimentation, chronic lesions 
were observed in all of them. Among the 13 untreated animals, 10 had visible lung sequestra and 3 had 
cicatrical lesions indicative of resolved lung lesions. Conversely, among the 9 treated animals, only 1 
had a small lung sequestrum and the remaining 8 had pulmonary adhesions. The results presented 
demonstrate that, under the experimental conditions used, treatment with oxytetracycline did not result 
in significant sequestra formation in CBPP-infected animals. Full field validation is required in order to 
confirm these findings.  
 
Key words: Contagious bovine pleuropneumonia, antibiotherapy, oxytetracycline, Lung sequestra, experimental 
transmission, Mali. 
 
 
INTRODUCTION 
 
Contagious bovine pleuropneumonia (CBPP) is an 
important infectious disease of cattle caused by 
Mycoplasma mycoides subsp. mycoides SC (MmmSC) 
that is characterized by a severe fibrinous exudative 
pleuropneumonia. It used to  be  included  on  the  former  
 
 
 
*Corresponding author. E-mail: mniangm@yahoo.fr. Tel: +223 
2024 33 44. +254 20 3674 000. 
‘Office of International Epizooties’ the disease was 
included in the list A of diseases because of its high 
transboundary and infectious potential 
(http://www.oie.int). Now that rinderpest is largely under 
control in Africa, CBPP remains one of the most impor-
tant animal diseases in tropical Africa causing great eco-
nomic loss  due to animal mortality, weight loss, reduced 
working ability, reduced fertility and indirect costs due to 
control programmes (Tambi, 2006).   
In Africa attempts to control CBPP  by  stamping  out, a  
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combination of vaccination, animal movement manage- 
ment and quarantine of affected animals have  been  met 
with limited success because of the difficulties and finan-
cial costs of implementing such control measures (Sylla 
et al., 1995).The use of antibiotics to treat CBPP disease 
in the field is common, although official policy is contrary 
to this practice, due to the possibility of creating carrier 
animals which are thought to be sources of fresh infection 
in a herd, development of antimicrobial resistance and 
anti-biotic residues in meat and milk products (FAO, 
1967). Currently, there is little or no experimental evi-
dence to support the hypothesis of carrier status created 
by the use of antibiotics for CBPP disease treatment. 
Studies are therefore, urgently needed in this area to 
further elucidate the role of antibiotics in the generation or 
not of carriers of CBPP disease (FAO, 2002).  
This study was therefore, conducted with the principal 
objective of assessing the role of long-acting oxytetra-
cycline treatment in the development of sequestra in 
CBPP-infected animals. This antibiotic is the most widely 
used antibacterial agent in the field throughout many 
African countries. 
 
 
METHODLOGY 
 
Experimental animals 
 
Thirty five clinically healthy zebu cattle, 3 - 6 years old and negative 
for MmmSC antibodies as tested by competitive enzyme linked-
immunosorbent assay (c-ELISA), were purchased from several 
herds and conveyed to facilities at the Central Veterinary 
Laboratory (CVL), Bamako, Mali. Upon arrival, the animals were 
ear-tagged for identification and underwent a two-month mandatory 
quarantine period during which they were bled twice to establish 
their serological status with regards to CBPP disease. The animals 
were also treated against internal and external parasites and 
vaccinated against pasteurellosis and blackleg infections. 
 
 
Experimental infection 
 
After the quarantine phase, 21 of the 35 animals were artificially 
infected with MmmSC field isolate (No 342/07) by intra-tracheal 
intubation. The strain used was isolated from an active CBPP field 
outbreak in Mali and stored at the CVL mycoplasma isolate bank at 
-80°C. Mycoplasma organisms were cultured in Gourlay medium at 
37°C and harvested in log phase growth by centrifugation at 10 000 
× g for 20 min and washed once in PBS buffer. The number of 
organisms was determined by microtitration in liquid media and 
concentration was adjusted to 5 × 108 CFU (colony forming units) in 
PBS buffer. While awaiting the results of the microtitration, the 
organisms were kept at -80°C. 
For the intra-tracheal intubation method, a lubricated 11 mm 
outer diameter polyethylene nasal-oesophageal tubing (broncho-
scope) was inserted into the nostril of the animal and pushed gently 
along the nasal septum until seated firmly in a bronchus. Usually, a 
cough reflex indicated the successful delivery to the bronchus. Fifty 
ml of mycoplasma organisms (5 × 108) were delivered into the lung 
followed by 50 ml of sterile 1.5% of agar solution to rinse the 
bronchoscope (Dedieu et al., 2005). Intubated animals were kept 
apart, checked daily for body temperature and other symptoms 
suggestive of CBPP disease (coughing and dyspnea), to observe 
disease progression.  
 
 
 
 
Upon the manifestation of the first clinical signs of illness (10 – 15 
days post intubation), the 21 animals were added to the remaining 
14 animals in order to reproduce the disease by contact exposure. 
Animals were tagged with numbers from I1 to I21 for the intubated 
animals (I) and from C1 to C14 for the contact-exposed (C) animals. 
To increase the pressure of infection, the intubated animals and the 
contact-exposed animals were kept in permanent and close contact 
in an isolated and secured pen. They spent the daytime in the 
courtyard of the pen with free access to feed and water, and in 
confinement within the pen at nighttime (Niang et al., 2004).  
 
 
Antibiotic treatment 
 
In order to assess the effect of long acting oxytetracycline treatment 
in the development of sequestra in CBPP-infected animals, 9 
animals comprising of 3 intubated animals (I2, I3 and I5) and 6 
contact-exposed animals (C1, C2, C4, C7, C11, and C14) were 
treated, upon the first evidence of clinical signs of illness 
(respectively, 10 - 15 days post intubation and 24 - 73 days post 
contact) with long acting oxytetracycline (20%) following the 
manufacturer’s instructions (dose rate of 1 ml/10 kg of body weight). 
The treatment started with varying periods after infection, but still 
immediately following manifestation of the clinical signs. The 26 
remaining animals comprising 18 intubated animals and 8 contact-
exposed animals were left untreated and served as control animals.   
 
 
Clinical and post-mortem examinations 
 
Animals were observed daily for signs of clinical disease including 
cough, nasal discharge, lethargy, respiratory distress, anorexia, 
weight loss and eye discharges. In addition, rectal temperatures 
and respiratory rates were recorded within two-day intervals over a 
period of 49 weeks post-infection. 
Post-mortem examinations were performed on animals that died 
or were culled in extremis during the experimentation or those that 
were slaughtered at the end of the experimentation that lasted 
approximately 10 months. Lungs and adjoining regional lymph 
nodes were thoroughly examined for gross pathological lesions 
suggestive of CBPP (specifically the presence of lung sequestra, 
the determination of their size and consistency).  
 
 
Sample collection  
 
From all the animals, serum samples were collected sequentially at 
one week intervals during the first month post-infection and then 2 - 
4 week intervals during the remaining period of experimentation. 
Blood for serum samples were allowed to clot at room temperature 
and centrifuged to harvest the serum samples that were aliquoted 
and stored at -20°C until tested for specific antibodies (Ab) to 
MmmSC by cELISA and the complement fixation test (CFT).  
Tracheobronchial lavage fluids were collected only once from the 
intubated animals immediately following the onset of the disease 
and then from all remaining intubated and contact-exposed animals 
at slaughtering. Samples of lung tissues, pleural fluid, lung 
sequestra, lymph nodes and kidneys were also collected from 
animals which died during the experiment or were slaughtered at 
the end of the experimentation.   
Samples of tracheobronchial lavage fluid, lung tissues, pleural 
fluid, lung sequestra, kidney tissues and lymph nodes were pro-
cessed immediately for mycoplasma isolation. 
 
 
Laboratory analysis 
 
For isolation of MmmSC, ten-fold serial dilutions of each sample 
were made in Gourlay and Brain Heart Infusion (BHI) broth  media.  
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Table 1. Scale of animal scoring system.  
 
Indicators of infection  Score 
1. Serology (c-ELISA PI)  
PI < 40 0 
PI = 40-50 1 
PI >50 2 
 
2. Pyrexia  
< 38.5°C  0 
38.5°C - 39.5°C 1 
> 39.5°C 2 
 
3. Lethargy  
absent 0 
mild 1 
severe 2 
  
4. Cough frequency  
Absent 0 
Moderate 1 
Severe 2 
  
5. Pulsation  
< 63 0 
= 63 – 70 1 
> 70 2 
 
6. Respiratory frequency  
< 22 0 
= 22 – 25 1 
> 25 2 
  
7. Animal died from the disease 2 
  
8. Autopsy results  
Active lesions (hepatisation and pleural fluid) 2 
Size of chronic lesions (sequestrum)  
Absent 0 
< 5 cm 1 
5 – 20 cm  2 
> 20cm  3 
  
Resolving lesions (fibrotic scars and adhesions) 1 
 
PI (Percentage of Inhibition). 
 
 
 
Confirmation of MmmSC was made by growth inhibition test on 
solid medium after two to three sub-passages in liquid medium. To 
test specific antibodies to MmmSC in serum samples, CFT and 
cELISA were both carried out according to the protocols provided 
with the kits (CIRAD-EMVT, Montpellier, France). The CFT was 
carried out on two fold serial dilutions of heat inactivated (56°C for 
30 min) serum samples. The cELISA was carried out using a single 
1:10 dilution of raw serum samples.  
Animal scoring system 
 
In an attempt to integrate the various criteria of infection (clinical 
signs, post-mortem findings, mycoplasma isolation and serological 
responses) recorded during the experimental period, for a better 
evaluation of animal status, a scoring system scale for CBPP 
according to Hudson and Turner (1963) was adopted as indicated 
in Table 1.  
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Table 2. Summary of clinical, pathological, microbiological and serological data on animals within the untreated group. 
 
Animal 
No Clinical disease Gross lung lesions Laboratory results 
 Main clinical signs recorded Disease 
outcome 
Type of 
lesions Size of sequestra 
MmmSC 
Isolation c-ELISA 
I1 Cough, weakness, lethargy, diarrhea Death A, H NA + (B, L) + 
 
      
I4 Cough, nasal discharge, dyspnea, prostration, difficulty of movement  Death A, H, PF NA + (B, L, PF) + 
 
      
I6 Cough, dyspnea, lethargy Recovery A, S (multiple) Large (6/10 cm) (6/15 cm) + (B) + 
 
      
I7 Cough, dyspnea, lethargy Recovery A, S Large (14/18 cm) + (B, S) + 
 
      
I8 Cough, nasal discharge, diarrhea, prostration, difficulty of movement Death H NA + (B, L) - 
 
      
I9 Cough, dyspnea, lethargy, weakness Recovery A, S Large (7/15 cm) + (B) + 
I10 Cough, dyspnea, nasal discharge, lethargy Recovery A, S Large (8/15 cm) + (B) + 
I11 Cough, dyspnea, nasal discharge, lethargy Recovery A, S Large (4/15 cm) + (B) + 
I12 Cough, lethargy Death A, H NA + (B) + 
I13 Cough, lethargy Recovery A, H, CL NA + (B) + 
I14 Cough, nasal discharge, dyspnea, weakness Recovery A, S (liquid) Large (5/15 cm) + (B) + 
I15 Cough, diarrhea, weakness, lethargy Death H NA + (B, L) - 
I16 Cough, dyspnea, weakness Death A, H, PF NA + (B, L, PF) - 
I17 Cough, nasal discharge, lethargy Recovery A, H, CL NA + (B) + 
I18 Cough, nasal discharge, dyspnea, weakness Death A, H NA + (B, L) - 
I19 Cough, lethargy Recovery A, S Large (6/13 cm) + (B) + 
I20 Cough, lethargy Recovery A, S Small (3/5 cm) + (B, S) + 
 
      
I21 Cough, diarrhea, lethargy, difficulty of 
movement  Death A, H NA + (B, L) + 
 
      
C3 Cough Recovery A NA - + 
C5 Cough, lethargy Death H, PF NA + (L, PF) + 
C6 Cough, lethargy Death A, H, PF NA + (L, PF) - 
C8 Cough, lethargy Death H, PF NA + (L) - 
C9 Cough, lethargy Death A, H, PF NA + (L, PF) + 
C10 Cough, lethargy  Death Absence NA - + 
C12 Cough, lethargy Recovery A, S Large (8/9 cm) + (S) + 
C13 Cough, lethargy Recovery A, S Large (11/21 cm) - + 
 
A (Lung adherence); H (Lung hepatization); PF (Pleural fluid); S (Sequestrum); CL (Cicatrical lesions); B (Bronchoalveolar lavage fluid); L (Lung);  NA 
(Not applicable); + (Positive); - (Negative). 
 
 
 
Statistical analysis 
 
Because of the small sample size, the Fishers Exact test was used 
to compare the various parameters of infection in animals within the 
treated and untreated groups. The Wilcoxon–Mann–Whitney test, 
which uses non-parametric analysis of two populations having the 
same location, was used to test differences of total clinical scores 
between the 2 groups. 
RESULTS 
 
Results of the overall clinical outcome (including course 
of clinical signs and mortality), the pathology, the 
frequency and size of sequestra, the serology and the 
isolation of mycoplasmas within both untreated and 
treated   groups  were  summarized  in  Tables  2  and  3,  
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Table 3. Summary of clinical, pathological, microbiological and serological data on animals within the treated group with long-acting 
oxytetracycline. 
 
Animal No 
Clinical disease Gross lung lesions Laboratory results 
Main clinical signs recorded Disease 
outcome 
Type of 
lesions Size of sequestra 
MmmSC 
Isolation c-ELISA 
I2 Cough, nasal discharge, lethargy Recovery A NA + (B) + 
I3 Cough, lethargy Recovery A NA + (B) + 
I5 Cough, nasal discharge, lethargy Recovery A, CL NA + (B) + 
C1 Cough Recovery A NA - + 
C2 Cough Recovery A NA - + 
C4 Cough Recovery A NA - + 
C7 Cough Recovery A, S Small (0.1/0.2 cm) - + 
C11 Cough, lethargy Recovery A NA - + 
C14 Cough, lethargy Recovery A NA - + 
 
A (Lung adherence); S (Sequestrum); CL (Cicatrical lesions); B (Bronchoalveolar lavage fluid); NA (Not applicable); + (Positive); - (Negative). 
 
 
 
 
 
Figure 1. Acute clinical form of CBPP observed in an untreated animal (I4) 
one month after intubation. Note the neck extension of the animal indicating a 
respiratory distress. Saliva is leaking from the mouth. 
 
 
 
respectively.  
 
 
Clinical and post-mortem findings on animals within 
the untreated group 
 
All of the 26 untreated animals comprising 18 in the 
intubated group and 8 in the contact-exposed group 
showed clinical signs of CBPP characterized by cough, 
prostration with difficulty of movement, dyspnea, nasal 
discharges and weakness (Table 2 and Figure 1). While 
the onset of the disease was rapid in the former group 
which varied from  10 -  15  days  post  intubation,  it  was 
delayed in the latter and varied from 24 - 73 days post 
contact. The recorded rectal temperatures were high and 
averaged around 40°C in both groups.  
Thirteen animals of which 8 in the intubated group (I1, 
I4, I8, I12, I15, I16, I18 and I21) and 5 in the contact-
exposed group (C5, C6, C8, C9 and C10) died during the 
course of the experimentation. At necropsy, acute 
pulmonary lesions characteristic of CBPP (lung 
hepatization and pleural fluid) were observed (Table 2, 
Figures 2, 3 and 4).  
The 13 remaining animals, 10 in the intubated group 
(I6, I7, I9, I10, I11, I13, I14, I17, I19 and I20) and 3 in the 
contact-exposed   group   (C3,   C12   and  C13)  showed 
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Figure 2. Acute gross lung lesions of CBPP in an untreated animal (C6). The 
thorax has been opened and an abundant quantity of clear yellow fluid (pleural 
liquid) is visible in the cavity. 
 
 
 
 
 
Figure 3. Acute gross lung lesions of CBPP in an untreated animal (I4). 
Note the volume and the consolidation of the left lung. 
 
 
 
clinical signs of the disease for a long period of time 
(approximately 4 - 5 months) and recovered thereafter. 
When they were slaughtered at the end of experi-
mentation, chronic lesions were observed in all of them. 
In the intubated group, 8 had visible lung sequestra (I6, 
I7, I9, I10, I11, I14, I19 and I20) and 2 had pleural 
adhesions and cicatrical lesions, indicative of resolved 
lung lesions (I13 and  I17).  Among  the  contact-exposed 
group, 2 animals (C12 and C13) had visible lung 
sequestra and the remaining one (C3) had pleural 
adhesions and cicatrical lesions, indicative of resolved 
lung lesions. In both groups, the sequestra were large 
and varied in size from about 5 - 21 cm in diameter 
(Table 2, Figures 5 and 6). The presence of multiple 
sequestra was observed only in one animal (I6). In some 
cases, the lymph nodes were inflamed. 
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Figure 4. Acute gross lung lesions of CBPP in an untreated animal (I4). On cross-section, the 
surface of the lung exuded large amount of serous fluid and showed a pronounced interlobular 
thickening with a marbled appearance. 
 
 
 
 
 
Figure 5. Chronic gross lung lesions with a visible sequestrum observed in an untreated animal 
(I10). On incision of sequestrum, the necrotic contents shelled out easily leaving a thick capsular 
wall. 
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Figure 6. Chronic gross lung lesion with adherence observed in 
an untreated animal (C12). 
 
 
 
Clinical and post-mortem findings on animals within 
treated group 
 
The 9 animals comprising 3 intubated animals (I2, I3 and 
I5) and 6 contact-exposed animals (C1, C2, C4, C7, C11 
and C14) that were treated with long-acting oxytetra-
cycline (20%) upon the first evident clinical signs of 
illness, recovered. The clinical signs of disease com-
pletely disappeared within 4 - 5 weeks after treatment 
(Table 3). 
When these animals were slaughtered at the end of 
experimentation, the lesions observed, consisted mainly 
of pleural adhesions. In contrast to the untreated animals,  
no evident sequestra were detected, except in one 
animal (C7) which showed a very small sequestrum 
(0.1/0.2 cm) (Table 3).  
 
 
Integrated scores of clinical, pathological, 
microbiological and serological data on animals 
within both untreated and treated groups  
 
The results of the integrated scores of each animal based 
on the various criteria of infection including course of 
clinical signs and mortality, the pathology, the frequency 
and size of sequestra, the mycoplasma recovery and the 
serological responses for both groups recorded during 
the whole experimental period are summarized in Table 
4.  
Considering all criteria with the exception of tem-
perature, pulse rate and respiratory frequency in which 
there was no significant difference between animals 
within the 2 groups, the others clinical criteria of infection 
were significantly lower in the animals within the treated 
group than in those within the untreated group (p > 0.01), 
and this was reflected in differences in the mortality rate 
(p   >  0.008)  observed,  the  mycoplasma  recovery  rate 
 
 
 
 
(p > 0.004) and the development of sequestra (p > 
0.002). Indeed, of the 26 animals within the untreated 
group, 13 animals died during the course of the 
experimentation and among those that survived 76.92% 
(10/13) developed sequestra. In contrast to the animals 
within the untreated group, all the animals within the 
treated group survived. Only one animal (1/9; 11.11%) 
presented a small sequestrum.  
Results of the two groups were also compared by 
examination of the total clinical scores. While the total 
clinical score of all the animals within the untreated group 
was 354, the animals within the treated group had a total 
score of 89 which was significantly lower (P > 0.0003). 
This score was still significantly lower (p > 0.002) when 
compared to that of the surviving animals within the 
untreated group which was 169.  
 
 
Serological responses 
 
As indicated in Table 2, using the cELISA, the majority of 
the animals (29 /35), irrespective of their status, 
seroconverted with high titers. Likewise, using CFT, 
seroconversion was observed in many animals (27/35) 
irrespective of their status.  
 
 
Mycoplasma isolation 
 
MmmSC was isolated from the samples of tracheo-
bronchial lavage fluids of all the intubated animals, 
irrespective of their status, collected during the early 
stage of the infection (Tables 2 and 3). In contrast, -
attempts to isolate mycoplasma from the samples of 
tracheobronchial lavage fluids collected at slaughtering 
were unsuccessful. Mycoplasma was isolated from the 
lung tissues of 7 animals that died from the disease (I1, 
I4, I8, I15, I16, I18 and I21) and from the sequestral 
contents of the lung of only 2 animals (I7 and I20).  As 
indicated in Table 2, none of these 9 animals were 
treated with the long-acting oxytetracycline. 
Attempts to isolate mycoplasma from tracheobronchial 
lavage fluids collected from all contact-exposed animals 
at slaughtering were unsuccessful. Mycoplasma was 
isolated from lung tissues collected from the animals (C5, 
C6, C8 and C9) that died during the course of the 
infection and from the sequestral contents of the lung of 
only one animal (C12). None of these animals was 
treated with the long-acting oxytetracycline as indicated 
in the Table 2. 
 
 
DISCUSSION  
 
Contagious bovine pleuropneumonia (CBPP) is 
considered a priority disease by the FAO-Emergency 
Prevention System for Transboundary Animal Diseases 
(FAO-EMPRES) and other organizations. Controlling  the  
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Table 4. Summary of integrated scores of clinical, pathological, microbiological and serological data on animals 
within both untreated and treated groups. 
 
Untreated animals 
Treated animals 
Died plus recovered Recovered only 
Animal N° Clinical score Animal N° Clinical score Animal N° Clinical score 
I1 17 I6 15 I2 14 
I4 18 I7 15 I3 9 
I6 15 I9 15 I5 10 
I7 15 I10 15 C1 9 
I8 16 I11 15 C2 9 
I9 15 I13 12 C4 8 
I10 15 I14 13 C7 10 
I11 15 I17 12 C11 12 
I12 16 I19 12 C14 8 
I13 12 I20 13   
I14 13 C3 10   
I15 11 C12 11   
I16 11 C13 11   
I17 12     
I18 13     
I19 12     
I20 13     
I21 16     
C3 9     
C5 16     
C6 14     
C8 14     
C9 15     
C10 9     
C12 11     
C13 11     
Total score 354 Total score 169 Total Score 89 
 
 
 
disease in African countries, however, poses a number of 
challenges; among which are the difficulties in the 
application of rigorous sanitary measures due to socio-
cultural and economic reasons. Another factor is the 
limited protection conferred by the current CBPP vaccine 
against the disease. Alternative means of controlling the 
disease including antibiotic treatment have always been 
discouraged without any scientific support. In fact, it has 
been a common belief that treatment of infected animals 
with antibiotics compromised the control of the disease 
by generating a large number of carrier animals (FAO, 
1967). For a long time, this understanding has prevented 
the use of antibiotic treatment in the control of the 
disease. Reviewing the literature, however, it seems that 
this perception has not been objectively assessed and 
there is a lack of empirical evidence to substantiate it.  
To address this gap in knowledge on the use of anti-
biotics for the control of CBPP, animal experimentations 
were conducted with the objective of assessing the effect 
of     long-acting     oxytetracycline      treatment     in   the  
development of sequestra in CBPP infected animals and 
the possible role of treated cattle in the spread of the 
disease.  
Overall, the results reported here, indicated that long-
acting oxytetracycline treatment did not have a significant 
effect on the formation of sequestra in CBPP-infected 
animals, since 76.92% (10/13) of infected and untreated 
animals developed sequestra when compared to the 
infected and treated animals in which only one animal 
(1/9; 11.11%) presented a small sequestrum. This 
difference was statistically significant between the two 
groups (p > 0.002). To the best of our knowledge, there 
have been no published studies on the role of long-acting 
oxytetracycline treatment in the development of 
sequestra in CBPP-infected animals. Therefore, the pre-
sent study provides the first experimental attempt to 
elucidate this issue.  
The suggestion that antibiotic therapy could create 
carrier animals (cattle developing sequestra) which can 
shed infectious organisms and generate new infections in  
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susceptible herds is frequently repeated in the literature 
(Turner, 1954; Provost et al., 1987; Masiga et al., 1996). 
However, it appears that this perception is not based on 
scientific experimentations and might be derived from 
extrapolations made from past treatments with 
novarsenobenzol which is an arsenic based product and 
not an antibiotic. The beneficial therapeutic action of this 
drug in a variety of general infections has been demon-
strated (Mornet, 1954). Orue and Memery (1961) showed 
the development of encapsulated lesions with high 
amounts of MmmSC organisms in cattle treated with 
novarsenobenzol. They did not demonstrate that these 
animals could transmit the disease to susceptible cattle. 
However, the authors suggested that these animals could 
have disastrous consequences in the epidemiology of the 
disease by excreting mycoplasmas and therefore, this 
therapy as well as any other chemical treatments 
including antibiotics, could favor, not only the persistence 
of the disease, but also its dissemination. It is precisely 
based on such untested assumptions that veterinary 
epidemiologists have called for the banning of antibiotics 
in the treatment of CBPP. However, there are some 
scientific data that prove the contrary. Windsor and 
Masiga (1977) were unable to transmit infection to 
susceptible cattle from naturally recovered cases har-
boring sequestra despite prolonged contact and stress. 
They also failed to produce active infection in recovered 
cattle harboring sequestra by contact with acute cases of 
the disease.  
The results reported also demonstrated that long-acting 
oxytetracycline treatment had a positive effect on the 
clinical course of the disease since all the 9 animals that 
were treated recovered and clinical signs of disease 
completely disappeared 4 - 5 weeks after treatment. 
Conversely, the untreated animals did not recover and 13 
animals died with acute lung lesions during the course of 
the experimentation. These results confirmed our 
previous experimentations (Niang et al., 2007) in which a 
high rate of recovery was obtained (10 animals out of 12) 
following the treatment of naturally CBPP infected cattle 
in an acute stage of the disease with long-acting oxytetra-
cycline. Treated animals also failed to transmit the 
disease to susceptible cattle. These are also in agree-
ment with the observations made by Windsor and Masiga 
(1977) and Yaya et al. (2003). Similarly, Camara (1971), 
Turner (1960), Hudson and Etheridge (1965) and the FAO 
Expert Panel (FAO, 1967) described the efficacy of 
tetracyclines, tylosin, erythromycin and many other 
antibacterial agents in treating CBPP. Huebschle et al. 
(2006) studying the effect of danofloxacin in the treatment 
of naturally infected cattle with CBPP and the role of 
these treated animals in the spread of the disease, have 
shown that although clinical and bacteriological cures 
could not be obtained, treatment significantly reduced the 
transmission of the disease to healthy in-contact animals. 
Nicholas et al. (2006) found a large reduction in clinical 
cases and death following treatment of CBPP-infected 
animals   with  Advocin  over  a  six-month  period  in  the  
 
 
 
 
Caprivi region of Namibia in which mortality and morbidity 
were occurring despite vaccination. The authors also 
indicated that animals at post-mortem examination were 
devoid of active lesions. Instead, chronic lesions 
consisting of pleuritis and extensive fibrosis or, infer-
quently, small encapsulated sequestra indicators which 
probably pose little risk to healthy contact cattle were 
detected. Interestingly, MmmSC could not be detected in 
any of these chronic lesions. These observations are in 
accordance with the study’s results in that all the CBPP 
lesions seen in animals treated with the oxytetracycline, 
consisted of adhesions and a small sequestrum in only 
one animal. All these chronic lesions were culturally 
negative for MmmSC.   
In conclusion, the results of this study demonstrated 
that treatment with oxytetracycline did not result in 
significant sequestra formation in CBPP-infected animals. 
Full field validation is required in order to confirm these 
findings. 
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